Relation of lower hematocrit to progression from asymptomatic left ventricular dysfunction to symptomatic heart failure (from the Studies of Left Ventricular Dysfunction Prevention Trial)

Sandeep R. Das, Daniel L. Dries, Mark H. Drazner, Clyde W. Yancy, Claudia U. Chae

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The relation between hematocrit and progression from asymptomatic left ventricular (LV) systolic dysfunction to symptomatic heart failure (HF) was examined in 2,821 patients from the Studies of Left Ventricular Dysfunction Prevention trial. Patients in the lowest hematocrit quartile (hematocrit ≤40%) were at increased risk for the development of HF symptoms (hazard ratio [HR] 1.79, 95% confidence interval [CI] 1.37 to 2.34), first HF hospitalization (HR 2.35, 95% CI 1.52 to 3.62), and death or the development of HF symptoms (HR 1.60, 95% CI 1.28 to 1.99) compared with patients in the highest hematocrit quartile (hematocrit >46%).

Original languageEnglish (US)
Pages (from-to)827-831
Number of pages5
JournalAmerican Journal of Cardiology
Volume96
Issue number6
DOIs
StatePublished - Sep 15 2005

Fingerprint

Left Ventricular Dysfunction
Hematocrit
Heart Failure
Confidence Intervals
Hospitalization

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{e6b2b888cc6547f9b29acc1201ccfa97,
title = "Relation of lower hematocrit to progression from asymptomatic left ventricular dysfunction to symptomatic heart failure (from the Studies of Left Ventricular Dysfunction Prevention Trial)",
abstract = "The relation between hematocrit and progression from asymptomatic left ventricular (LV) systolic dysfunction to symptomatic heart failure (HF) was examined in 2,821 patients from the Studies of Left Ventricular Dysfunction Prevention trial. Patients in the lowest hematocrit quartile (hematocrit ≤40{\%}) were at increased risk for the development of HF symptoms (hazard ratio [HR] 1.79, 95{\%} confidence interval [CI] 1.37 to 2.34), first HF hospitalization (HR 2.35, 95{\%} CI 1.52 to 3.62), and death or the development of HF symptoms (HR 1.60, 95{\%} CI 1.28 to 1.99) compared with patients in the highest hematocrit quartile (hematocrit >46{\%}).",
author = "Das, {Sandeep R.} and Dries, {Daniel L.} and Drazner, {Mark H.} and Yancy, {Clyde W.} and Chae, {Claudia U.}",
year = "2005",
month = "9",
day = "15",
doi = "10.1016/j.amjcard.2005.05.030",
language = "English (US)",
volume = "96",
pages = "827--831",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Relation of lower hematocrit to progression from asymptomatic left ventricular dysfunction to symptomatic heart failure (from the Studies of Left Ventricular Dysfunction Prevention Trial)

AU - Das, Sandeep R.

AU - Dries, Daniel L.

AU - Drazner, Mark H.

AU - Yancy, Clyde W.

AU - Chae, Claudia U.

PY - 2005/9/15

Y1 - 2005/9/15

N2 - The relation between hematocrit and progression from asymptomatic left ventricular (LV) systolic dysfunction to symptomatic heart failure (HF) was examined in 2,821 patients from the Studies of Left Ventricular Dysfunction Prevention trial. Patients in the lowest hematocrit quartile (hematocrit ≤40%) were at increased risk for the development of HF symptoms (hazard ratio [HR] 1.79, 95% confidence interval [CI] 1.37 to 2.34), first HF hospitalization (HR 2.35, 95% CI 1.52 to 3.62), and death or the development of HF symptoms (HR 1.60, 95% CI 1.28 to 1.99) compared with patients in the highest hematocrit quartile (hematocrit >46%).

AB - The relation between hematocrit and progression from asymptomatic left ventricular (LV) systolic dysfunction to symptomatic heart failure (HF) was examined in 2,821 patients from the Studies of Left Ventricular Dysfunction Prevention trial. Patients in the lowest hematocrit quartile (hematocrit ≤40%) were at increased risk for the development of HF symptoms (hazard ratio [HR] 1.79, 95% confidence interval [CI] 1.37 to 2.34), first HF hospitalization (HR 2.35, 95% CI 1.52 to 3.62), and death or the development of HF symptoms (HR 1.60, 95% CI 1.28 to 1.99) compared with patients in the highest hematocrit quartile (hematocrit >46%).

UR - http://www.scopus.com/inward/record.url?scp=24944468745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944468745&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2005.05.030

DO - 10.1016/j.amjcard.2005.05.030

M3 - Article

C2 - 16169371

AN - SCOPUS:24944468745

VL - 96

SP - 827

EP - 831

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 6

ER -